Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Overview of attention for article published in New England Journal of Medicine, September 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 30 news outlets
blogs: 3 blogs
twitter: 169 X users
video: 1 YouTube creator

guideline: 4 clinical guideline sources
bluesky: 2 Bluesky users
podcasts: 4 podcasts

Readers on

mendeley: 228 Mendeley

So far, Altmetric has seen 6 episodes from 4 podcasts.

Highlights From the 2026 ASCO GU Cancers Symposium

ASCO Daily News, 05 Mar 2026

Dr. Monty Pal and Dr. Andrea Apolo discuss practice-changing studies and other novel approaches in bladder, kidney, and…

Ep. 287 Urothelial Carcinoma: Understanding CTDNA and Precision Medicine with Dr. Amanda Nizam and Dr. Brad McGregor

BackTable Urology, 30 Jan 2026

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in…

Journal club #3 | ERSPC and NIAGARA

GU Cast | Urology Podcast, 27 Oct 2025

Episode 3 of our monthly GU Cast Journal Club and today we focus on one classic paper in Urology, and one from recent times …

Ep. 256 The Role of ctDNA in Bladder Cancer Diagnosis

BackTable Urology, 22 Aug 2025

Could ctDNA testing allow us to treat bladder cancer earlier, smarter, and more effectively? In this episode of BackTable…

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity, including 2 additional posts.